About Fleury Augustin Nsole Biteghe
Dr. Fleury A Nsole Biteghe is a lecturer under the MS in Biotechnology program at Northeastern University. He holds a PhD with specialization in Medical Biotechnology and Immunotherapy, from the University of Cape Town (UCT). As a postdoctoral scientist at Cedars Sinai hospital, he has contributed to elucidating immune resistant mechanisms causing immunotherapeutic treatment failures. He has over 12 years of academic and industrial research expertise focused on the development of antibody drug conjugates (ADCs) and photoconjugates (APCs) for photoimmunotherapeutic (PIT) application. Dr. Biteghe scientific efforts are focused on PIT, a novel light-dependent therapy utilizing the targeted binding of antibody-IR700 conjugate to a specific tumor antigen, with subsequent illumination, causing ROS production thereby inducing rapid cell death. After acquiring industry experience at Rakuten Medical and Takeda Oncology, Dr Biteghe joined Global Health Catalyst (GHC), an organization whose mission is to curb the growing cancer crisis and save millions of lives by catalyzing win-win collaborations for global health and innovation. Additionally, he is interested in developing the next generation of biotech entrepreneurs and improving biotech accessibility to underprivileged and historically disadvantaged communities, through his Nucleate activities. He has extensive experience in teaching biotechnology and enjoys translating his industry and research experience for academic application.
Publications:
-
Advances in Etiopathological Role and Control of HPV in Cervical Cancer OncogenesisRead
-
CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugateRead
-
Click Chemistry-Generated Auristatin F−Linker−Benzylguanine for a SNAP-Tag-Based Recombinant Antibody−Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor CellsRead
-
CD8+ T-cells Immune Escape by SARS-CoV-2 Variants of ConcernRead
-
Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a reviewRead
-
Detection of Circulating VZV-Glycoprotein E-Specific Antibodies by Chemiluminescent Immunoassay (CLIA) for Varicella–Zoster DiagnosisRead
-
Treatment of Chikungunya Virus (CHIKV) Using Targeted ImmunotherapyRead
-
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodiesRead
-
Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazineRead
-
Antibody-Based Immunotherapy : Alternative Approaches for the Treatment of Metastatic MelanomaRead
-
Effect of aqueous extracts of Ficus vogeliana Miq and Tieghemella africana Pierre in 7,12-Dimethylbenz(a)anthracene -induced skin cancer in ratsRead
-
Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin CancersRead
-
Applications of SNAP ‐ tag technology in skin cancer therapyRead
-
Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian CancerRead
-
A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cellsRead
-
Draft Genome Sequences of Three Bacillus Species from South African Marine SpongesRead
-
Enhancing Photodynamic Therapy in Skin Cancer: Important considerations to increase PDT efficacyRead